Target-Therapie: Präparate
| zurück Tumortherapie Home | Target-Therapie: Präparate | ||||
| Her1-IH | Erlotinib | Tarceva | 25/100/150mg | 30 Filmtabletten | |
| Gefinib | Iressa | ||||
| Cetuximab | Erbitux | stationär ab 250mg Sonderentgelte. | |||
| Panitumab | Vectibrix | ||||
| Her2/neu-IH. | Trastuzumab | Herceptin | |||
| Lapatinib | Tyverb | ||||
| BCR-ABL TK-IK | Imatinib | Glivec | |||
| Sunitinib | Sutent | ||||
| Sorafenib | Nexavar | ||||
| Pazopanib | Votrient | ||||
| Dasatinib | Sprycel | ||||
| Nilotinib | Tasigna | ||||
| Rituximab | MabThera | ||||
| Ibritumomab | Zevalin | ||||
| Angiogenese-Hemmer | Bevacizumab | Avastin | |||
| T-VDA | DMXAA, ASA404 | Vadimezan | |||
| Ranibizumab | Lucentis | ||||
| Proteasom-IH | Bortezomib | Velcade | 1 / 3,5mg Durchstechflasche, 1 /3,5ml Lösung | i.v. Bolusinjektion | |
| mTOR | Everolismus | Afinitor | |||
| Temsirolimus | Torisel | ||||
| ALK | XALKORI | 200/250 mg | 60 Hartkapseln | ||
| DAC | Panobinostat | ||||
| HDAC, Histon - Deacetylase IH | Vorinostat | ||||
| CYP17-IH | Abirateron | Zytiga® | |||
| CD | CD-52-AK | Alemtuzumab | 30mg i.v. | ||
| TGF-β-IH | Pirfenidon | Esbriet® | |||
| TNF-IH | Infliximab, Remikade® | Etanercept | Adalimumab, Humira® | Golimumab | |
| IL6 - IH | Siltuximab, SYLVANT® | Tocilizumab, RoActemra® | |||
| Janus-Kinase - IH | Tofacitinib | ||||
| RANK-L | Denusomab | XGEVA® | |||
| Immunmodulatoren | Thalidomid | Celgene® | |||
| Lenalidomid | |||||
| Pomalidomid | |||||
|
. | ||||
Impressum Zuletzt geändert am 08.02.2013 23:51